zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2023 / The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.

The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.

2023-05-02

Published Date:2023-05-02

Original Link:https://www.onenessbio.com/en/news_detail217_3.htm

No 2 Date of announcement 2023/05/02 Time of announcement 17:53:30
Subject The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.
To which item it meets paragraph 12 Date of events 2023/05/05
Statement
  1. Date of institutional investor conference:2023/05/05
  2. Time of institutional investor conference:19:30 (TPE time)
  3. Location of institutional investor conference:Milan, Italy
  4. Outline of institutional investor conference:
    (1)The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at European Wound Management Association (EWMA) 2023.
    (2)The European Wound Management Association (EWMA) was founded in 1991. Every year, EWMA attracts over 3,000 health professional participants from more than 80 countries.
  5. Any other matters that need to be specified:The presentation slides will be uploaded to Market Observation Post System according to the regulation.